Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/30/25
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual MeetingGlobeNewsWire • 10/29/25
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune DiseasesGlobeNewsWire • 10/16/25
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual MeetingGlobeNewsWire • 10/02/25
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/11/25
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public OfferingGlobeNewsWire • 09/10/25
Dianthus Therapeutics, Inc. - Discusses On Phase 2 MaGic Data Presentation Conference CallSeeking Alpha • 09/09/25
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public OfferingGlobeNewsWire • 09/08/25
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged AgainInvestors Business Daily • 09/08/25
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class ProfileGlobeNewsWire • 09/08/25
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia GravisGlobeNewsWire • 09/07/25
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/25
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial ResultsGlobeNewsWire • 08/07/25
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to DeclineZacks Investment Research • 08/07/25
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/29/25
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/12/25
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial ResultsGlobeNewsWire • 05/12/25
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in SeptemberGlobeNewsWire • 05/05/25
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/03/25
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial ResultsGlobeNewsWire • 03/11/25
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of DirectorsGlobeNewsWire • 03/05/25